The Epidemiology of Neuroendocrine Tumors in Taiwan: A Nation-Wide Cancer Registry-Based Study

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Tsai, Hui Jen ^a,b,c,d   Wu, Chun Chieh ^c   Tsai, Chia Rung ^a   Lin, Sheng Fung ^c   Chen, Li Tzong ^a,b,c,e   Chang, Jeffrey S ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; APPENDIX CANCER; ARTICLE; BILE DUCT CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CHILD; COLON CANCER; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NORWAY; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RECTUM CANCER; SCHOOL CHILD; SEX RATIO; SMALL INTESTINE CANCER; STOMACH CANCER; SURVIVAL RATE; TAIWAN; UNITED STATES; ADOLESCENT; AGE DISTRIBUTION; INCIDENCE; MIDDLE AGED; NEUROENDOCRINE TUMORS; REGISTER; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; REGISTRIES; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TAIWAN; YOUNG ADULT;

EID: 84876450428     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062487     Document Type: Article

References (35)

1. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, et al. (2008) Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113: 2655-2664.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, et al. (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072.
3. Oberg KE, (2010) Gastrointestinal neuroendocrine tumors. Ann Oncol 21 (Suppl 7):: vii72-80.
4. Oberg KE, (2012) The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol) 24: 282-293.
5. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, et al. (2010) Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45: 234-243.
6. Bureau of Health Promotion, Department of Health, the Executive Yuan, Taiwan. Cancer Registry Annual Report, Taiwan. Available: http://www.bhp.doh.gov.tw. Accessed: 2012 Sept 25.
7. Bray F, Parkin DM, (2009) Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer 45: 747-755.
8. Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, et al. (2009) Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 45: 1218-1231.
9. Shin HR, (2008) Global activity of cancer registries and cancer control and cancer incidence statistics in Korea. J Prev Med Public Health 41: 84-91.
10. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, et al. (2008) Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer 123: 867-873.
11. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, et al. (2008) Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 17: 959-965.
12. Wiedenmann B, Pavel M, Kos-Kudla B, (2011) From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors. Neuroendocrinology 94: 177-190.
13. Caldarella A, Crocetti E, Paci E, (2011) Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry. Pathol Oncol Res 17: 759-763.
14. Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R, (2009) The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 90: 349-363.
15. Hemminki K, Li X, (2001) Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92: 2204-2210.
16. Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, et al. (2012) Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat 44: 157-165.
17. Niederle MB, Hackl M, Kaserer K, Niederle B, (2010) Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 17: 909-918.
18. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, et al. (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21: 1794-1803.
19. Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C, et al. (2004) Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 53: 549-553.
20. Lepage C, Rachet B, Coleman MP, (2007) Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 132: 899-904.
21. Boyle P, Levin B (2008) World Cancer Report. Lyon: International Agency for Research on Cancer.
22. Johnson R, Trocha S, McLawhorn M, Worley M, Wheeler G, et al. (2011) Histology, not lymph node involvement, predicts long-term survival in bronchopulmonary carcinoids. Am Surg 77: 1669-1674.
23. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, et al. (2001) Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 119: 1647-1651.
24. Aydin E, Yazici U, Gulgosteren M, Agackiran Y, Kaya S, et al. (2011) Long-term outcomes and prognostic factors of patients with surgically treated pulmonary carcinoid: our institutional experience with 104 patients. Eur J Cardiothorac Surg 39: 549-554.
25. Li AF, Hsu CY, Li A, Tai LC, Liang WY, et al. (2008) A 35-year retrospective study of carcinoid tumors in Taiwan: differences in distribution with a high probability of associated second primary malignancies. Cancer 112: 274-283.
26. Modlin IM, Lye KD, Kidd M, (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934-959.
27. Sun L, Sakurai S, Sano T, Hironaka M, Kawashima O, et al. (2009) High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma. Pathol Int 59: 522-529.
28. Naranjo Gomez JM, Gomez Roman JJ, (2010) Behaviour and survival of high-grade neuroendocrine carcinomas of the lung. Respir Med 104: 1929-1936.
29. Tsuta K, Liu DC, Kalhor N, Wistuba, II, Moran CA, (2011) Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol 136: 252-259.
30. Ali G, Boldrini L, Capodanno A, Pelliccioni S, Servadio A, et al. (2011) Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Exp Ther Med 2: 787-792.
31. Lee HW, Lee EH, Ha SY, Lee CH, Chang HK, et al. (2012) Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumors. Pathol Int 62: 583-591.
32. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, et al. (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26: 4311-4318.
33. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, et al. (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28: 69-76.
34. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, et al. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523.
35. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, et al. (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501-513.